Angeles Wealth Management LLC Acquires 1,187 Shares of Thermo Fisher Scientific Inc. $TMO

Angeles Wealth Management LLC boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 32.8% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 4,808 shares of the medical research company’s stock after acquiring an additional 1,187 shares during the quarter. Angeles Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $2,332,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. First Trust Advisors LP raised its position in shares of Thermo Fisher Scientific by 54.6% during the third quarter. First Trust Advisors LP now owns 64,657 shares of the medical research company’s stock worth $31,360,000 after purchasing an additional 22,844 shares during the period. Neo Ivy Capital Management lifted its stake in Thermo Fisher Scientific by 426.1% in the third quarter. Neo Ivy Capital Management now owns 4,772 shares of the medical research company’s stock valued at $2,315,000 after buying an additional 3,865 shares in the last quarter. Ramirez Asset Management Inc. boosted its holdings in shares of Thermo Fisher Scientific by 36.8% in the third quarter. Ramirez Asset Management Inc. now owns 3,099 shares of the medical research company’s stock valued at $1,503,000 after buying an additional 834 shares during the period. Chapman Financial Group LLC boosted its stake in Thermo Fisher Scientific by 10.1% in the 3rd quarter. Chapman Financial Group LLC now owns 5,429 shares of the medical research company’s stock worth $2,633,000 after purchasing an additional 497 shares during the period. Finally, Marietta Investment Partners LLC raised its stake in shares of Thermo Fisher Scientific by 12.3% in the 3rd quarter. Marietta Investment Partners LLC now owns 6,667 shares of the medical research company’s stock valued at $3,234,000 after purchasing an additional 730 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $541.20, for a total value of $216,480.00. Following the completion of the sale, the executive vice president owned 20,752 shares of the company’s stock, valued at approximately $11,230,982.40. This trade represents a 1.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Down 3.3%

Thermo Fisher Scientific stock opened at $501.72 on Friday. The company’s 50-day moving average price is $567.28 and its two-hundred day moving average price is $548.32. The company has a quick ratio of 1.53, a current ratio of 1.89 and a debt-to-equity ratio of 0.67. The stock has a market cap of $186.38 billion, a P/E ratio of 28.28, a P/E/G ratio of 2.99 and a beta of 0.96. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, topping analysts’ consensus estimates of $6.45 by $0.12. The company had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The firm’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the company earned $6.10 earnings per share. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Friday, March 13th will be given a dividend of $0.47 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Friday, March 13th. Thermo Fisher Scientific’s payout ratio is 9.70%.

Analyst Ratings Changes

TMO has been the topic of a number of recent research reports. Robert W. Baird set a $653.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Morgan Stanley boosted their price target on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Friday, January 9th. Evercore reaffirmed an “outperform” rating and set a $650.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. Finally, UBS Group reiterated a “neutral” rating and issued a $615.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $633.68.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.